このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Waters 過去の業績

過去基準チェック /26

Watersは、平均年間4.4%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間成長しています。収益は、平均年間19.6% 6%収益成長率で成長しています。 Watersの自己資本利益率は48%であり、純利益率は20.7%です。

主要情報

4.4%

収益成長率

8.1%

EPS成長率

Life Sciences 業界の成長	36.9%
収益成長率	6.0%
株主資本利益率	48.0%
ネット・マージン	20.7%
前回の決算情報	30 Mar 2024

Recent updates

収支内訳

Waters の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

LSE:0LTI 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Mar 24	2,909	604	690	177
31 Dec 23	2,956	642	697	175
30 Sep 23	2,995	653	729	179
01 Jul 23	2,992	675	696	180
01 Apr 23	2,966	689	682	178
31 Dec 22	2,972	708	658	176
01 Oct 22	2,950	697	658	171
02 Jul 22	2,901	702	645	170
02 Apr 22	2,868	705	641	171
31 Dec 21	2,786	693	627	168
02 Oct 21	2,736	695	606	165
03 Jul 21	2,671	660	563	158
03 Apr 21	2,509	616	541	144
31 Dec 20	2,365	522	555	141
26 Sep 20	2,295	504	507	138
27 Jun 20	2,278	515	524	138
28 Mar 20	2,358	537	522	143
31 Dec 19	2,407	592	526	143
28 Sep 19	2,405	577	582	144
29 Jun 19	2,406	580	584	145
30 Mar 19	2,403	591	589	144
31 Dec 18	2,420	594	585	143
29 Sep 18	2,392	55	543	140
30 Jun 18	2,380	51	550	139
31 Mar 18	2,342	27	540	136
31 Dec 17	2,309	20	545	133
30 Sep 17	2,251	548	512	130
01 Jul 17	2,212	537	501	127
01 Apr 17	2,190	533	502	127
31 Dec 16	2,167	522	512	125
01 Oct 16	2,125	498	508	121
02 Jul 16	2,099	490	509	121
02 Apr 16	2,057	467	502	119
31 Dec 15	2,042	469	493	119
03 Oct 15	2,040	469	498	119
04 Jul 15	2,032	467	496	116
04 Apr 15	2,019	457	501	112
31 Dec 14	1,989	432	502	108
27 Sep 14	1,971	422	501	106
28 Jun 14	1,935	406	500	102
29 Mar 14	1,904	399	495	100
31 Dec 13	1,904	450	493	101
28 Sep 13	1,861	484	484	99
29 Jun 13	1,853	485	479	99

質の高い収益: 0LTIは高品質の収益を持っています。

利益率の向上: 0LTIの現在の純利益率 (20.7%)は、昨年(23.2%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 0LTIの収益は過去 5 年間で年間4.4%増加しました。

成長の加速: 0LTIは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: 0LTIは過去 1 年間で収益成長率がマイナス ( -12.4% ) となったため、 Life Sciences業界平均 ( -1.7% ) と比較することが困難です。

株主資本利益率

高いROE: 0LTIの自己資本利益率 ( 48.03% ) は抜群ですが、負債レベルが高いためこの指標は歪んでいます。

Waters 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

First quarter 2024 earnings released: EPS: US$1.73 (vs US$2.39 in 1Q 2023)

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Third quarter 2023 earnings released: EPS: US$2.28 (vs US$2.61 in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$2.74 in 2Q 2022)

First quarter 2023 earnings released: EPS: US$2.39 (vs US$2.64 in 1Q 2022)

Recent updates

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings released: EPS: US$1.73 (vs US$2.39 in 1Q 2023)

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Waters Corporation, Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Third quarter 2023 earnings released: EPS: US$2.28 (vs US$2.61 in 3Q 2022)

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Now 20% undervalued after recent price drop

Waters Corporation Launched OligoWorks SPE Workflow and Kits

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$2.74 in 2Q 2022)

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

First quarter 2023 earnings released: EPS: US$2.39 (vs US$2.64 in 1Q 2022)

Independent Director recently bought US$998k worth of stock

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

Full year 2022 earnings released: EPS: US$11.80 (vs US$11.25 in FY 2021)

Waters Corporation Announces Waters_Connect™ System Monitoring

Waters Corporation Announces Executive Changes

Independent Director recently sold US$354k worth of stock

High number of new directors

Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to Waters_Connect Informatics Platform

Third quarter 2022 earnings released: EPS: US$2.61 (vs US$2.63 in 3Q 2021)

Waters Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Waters Automates Solid Phase Extraction of Biological, Food and Environmental Samples with Andrew+ Pipetting Robot

Waters Extends Capabilities of Flagship Ta Instruments Rheometer for Efficient and Repeatable Powder Analysis

Now 22% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: US$2.74 (vs US$2.71 in 2Q 2021)

Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 1, 2022 and Full Year Ending December 31, 2022

Waters Corporation to Report Q2, 2022 Results on Aug 02, 2022

Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index

Waters Corporation Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Waters Corporation Provides Earnings Guidance for the Quarter Ending July 2, 2022 and Full Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$2.64 (vs US$2.38 in 1Q 2021)

Waters Corporation, Annual General Meeting, May 24, 2022

Waters Corporation Announces Resignation of John Ballbach from the Board of Directors

Waters Introduces Xevo TQ Absolute

Now 21% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 2, 2022 and Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS US$2.63 (vs US$2.05 in 3Q 2020)

High number of new directors

High number of new directors

Independent Director Michael Berendt has left the company

Waters Corporation Introduces the Waters™ BioAccord™ System

Lead Independent Director recently sold US$3.4m worth of stock

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2021

Second quarter 2021 earnings released: EPS US$2.71 (vs US$1.99 in 2Q 2020)

Waters Corporation Introduces TRIOS AutoPilot Software

Waters Corp. Introduces the Waters Arc Premier System

Waters Corporation Introduces the Sars-Cov-2 Lc-Ms Kit (Ruo) to Advance Clinical Research of Infectious Diseases

Independent Director recently sold US$369k worth of stock

Independent Director has left the company

First quarter 2021 earnings released: EPS US$2.38 (vs US$0.86 in 1Q 2020)

Waters Corporation Provides Earnings Guidance for the Three Months Ended July 3, 2021 and for the Full Year Ended December 31, 2021

Waters Corporation Introduces A New Peptide Multi-Attribute Method Workflow for the Waters BioAccord LC-MS System

Waters Corporation Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector

Full year 2020 earnings released: EPS US$8.40 (vs US$8.76 in FY 2019)

Revenue beats expectations

Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link

Full year 2020 earnings released: EPS US$8.40 (vs US$8.76 in FY 2019)

Revenue beats expectations

Waters Corporation Introduces the OttoTM SPEcialist Positive Pressure Manifold

Waters Corporation's APGC-MS/MS System Accepted for Advanced Dioxin and Furan Analysis Following USEPA Approval of SGS AXYS Method 16130

過去基準チェック /26